Antibody that binds to clostridioides difficile cells
Antibodies targeting Clostridioides difficile bacteria address the limitations of existing treatments by inhibiting bacterial growth, offering a promising therapeutic approach for inflammatory bowel diseases and improving intestinal health.
Patent Information
- Application Number
- PCT/JP2024/017523
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-10
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
Current treatments for inflammatory bowel diseases related to intestinal flora, particularly those caused by Clostridioides difficile, are inadequate due to antibiotic resistance and the instability of fecal transplantation methods, with existing antibody therapies only addressing toxins rather than the bacteria themselves.
Development of antibodies and antigen-binding fragments that specifically bind to Clostridioides difficile bacteria, inhibiting their growth and proliferation, along with methods for producing and administering these antibodies to treat intestinal diseases.
The antibodies effectively suppress the growth of Clostridioides difficile bacteria and improve intestinal flora, providing a potential therapeutic solution for inflammatory bowel diseases and other conditions associated with dysbiosis.
Smart Images

Figure JPOXMLDOC01-APPB-I000001 
Figure JPOXMLDOC01-APPB-I000002 
Figure JPOXMLDOC01-APPB-I000003
Abstract
Description
Antibodies that bind to Clostridioides difficile
[0001] The present disclosure relates to antibodies and antigen-binding fragments thereof that bind to Clostridioides difficile bacteria (C. difficile bacteria) and have the effect of inhibiting their growth, as well as uses of the antibodies.
[0002] The intestinal tract is essentially "outside the body" for the living body, and is therefore constantly exposed to a large number of diverse intestinal bacteria, viruses, food-derived antigens, etc. These intestinal bacteria form the intestinal flora.
[0003] It has been revealed that this intestinal flora performs various functions for the body through the mucosal surface composed of intestinal epithelial cells, etc., and it is also known that without the presence of intestinal bacteria, the intestinal immune system cannot develop normally (Non-patent documents 1 to 3).
[0004] When the intestinal flora changes and the symbiotic relationship with the host is disrupted, the intestinal immune system is overstimulated, disrupting its homeostasis and ultimately inducing many diseases such as inflammatory bowel disease, colon cancer, asthma, allergies, obesity, etc. For these reasons, it is known that the intestinal immune system not only eliminates pathogens, but also plays an important role in maintaining the homeostasis of the entire immune system (Non-Patent Documents 4 to 7).
[0005] Although numerous attempts have been made to control the intestinal flora using antibiotics, antibiotic-resistant bacteria have proven ineffective. Despite these efforts, many patients still suffer from C. difficile colitis and other inflammatory bowel diseases associated with the intestinal flora. While fecal transplants have been attempted as relatively new approaches, their therapeutic efficacy has not been consistent. As a result, several attempts have already been discontinued. Furthermore, the use of antibodies against toxins released by the intestinal flora as therapeutic agents has been researched and commercialized. However, because these antibody drugs only target toxins, treatments using these drugs are merely symptomatic. Therefore, the development of drugs to fundamentally treat inflammatory bowel diseases associated with the intestinal flora is desired.
[0006] C. difficile, a bacterium associated with inflammatory bowel disease (IBD), is a bacterium that, along with MRSA, is a cause of hospital-acquired infections and requires caution. In fact, U.S. statistics indicate that approximately 400,000–500,000 people are infected annually, resulting in approximately 15,000–20,000 deaths. C. difficile infections often occur in patients receiving long-term antibiotic therapy, and once infected, the recurrence rate is high (15–35%). Therefore, among the bacteria associated with IBD, there is a particularly strong demand for effective treatments. While current treatments involve powerful antibiotics such as vancomycin, these methods leave residual bacterial toxins and promote the development of antibiotic-resistant bacteria, necessitating the development of alternative treatments.
[0007] Cerf-Bensussan N, and Gaboriau-Routhiau V. , Nat Rev Immunol 2010;10:735 Hooper LV, and Macpherson AJ. , Nat Rev Immunol 2010;10:159Round JL, and Mazmanian SK, Proc Natl Acad Sci USA 2010;107:12204Vijay-Kumar M, et al. , Science 2010; 328:228 Shulzhenko N, et al. , Nat Med 2011;17:1585Bry L, et al. , Science 1996; 273:1380 Turnbaugh PJ, et al. , Nature 2006;444:1027
[0008] An objective of the present disclosure is to provide antibodies, and antigen-binding fragments thereof, that bind to C. difficile bacterial organisms, and uses thereof.
[0009] As a result of extensive research, the inventors of the present disclosure have discovered antibodies that bind to and inhibit the growth of enterobacteria, particularly C. difficile and other enterobacteria, and have also demonstrated that these antibodies bind to bacteria present in abnormal intestinal flora (dysbiosis).
[0010] In one aspect, the disclosure provides an antibody or antigen-binding fragment thereof that binds to and inhibits the growth of C. difficile bacterial organisms.
[0011] In one aspect, the disclosure provides immortalized cells that produce antibodies that bind to and inhibit the growth of C. difficile bacterial organisms.
[0012] In one aspect, the disclosure provides a composition comprising an antibody or antigen-binding fragment thereof that binds to and inhibits the growth of C. difficile bacterial organisms.
[0013] In one aspect, the disclosure provides methods for treating disease using antibodies or antigen-binding fragments thereof that bind to and inhibit the growth of C. difficile bacterial organisms.
[0014] In one aspect, the present disclosure provides the following: [Item 1] An antibody or antigen-binding fragment thereof that binds to Clostridioides difficile (C. difficile) bacteria and inhibits the growth of C. difficile, comprising: a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region represented by SEQ ID NO: 3; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region represented by SEQ ID NO: 4; or a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region represented by SEQ ID NO: 13; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region represented by SEQ ID NO: 14. [Item 2] The antibody or antigen-binding fragment thereof according to Item 1, comprising: a heavy chain CDR1 represented by SEQ ID NO: 5, a heavy chain CDR2 represented by SEQ ID NO: 6, and a heavy chain CDR3 represented by SEQ ID NO: 7; and a light chain CDR1 represented by SEQ ID NO: 8, a light chain CDR2 represented by SEQ ID NO: 9, and a light chain CDR3 represented by SEQ ID NO: 10. [Item 3] The antibody or antigen-binding fragment thereof according to Item 1, comprising a heavy chain CDR1 represented by SEQ ID NO: 15, a heavy chain CDR2 represented by SEQ ID NO: 16, a heavy chain CDR3 represented by SEQ ID NO: 17; and a light chain CDR1 represented by SEQ ID NO: 18, a light chain CDR2 represented by SEQ ID NO: 19, and a light chain CDR3 represented by SEQ ID NO: 20. [Item 4] A nucleic acid encoding the antibody or antigen-binding fragment thereof according to Item 1. [Item 5] An expression vector comprising the nucleic acid according to Item 4. [Item 6] A cell comprising the nucleic acid according to Item 4. [Item 7] A composition comprising the antibody or antigen-binding fragment thereof according to Item 1. [Item 8] The composition according to Item 7, which is in a freeze-dried state.
[0015] The present disclosure advantageously provides antibodies and antigen-binding fragments thereof that bind to Enterobacteriaceae, particularly C. difficile and other Enterobacteriaceae, and uses thereof.
[0016] Figure 1 shows the results of testing the binding ability of SNK0004 antibody and SNK0005 antibody to C. difficile bacteria. Figure 2 shows the results of testing the ability of SNK0004 antibody and SNK0005 antibody, as well as W27 antibody IgG1 type antibody (rW27IgG) and negative control IgA antibody (Control rIgA) to inhibit C. difficile growth. Figure 3 shows the results of evaluating the binding characteristics of individual bacterial species for bacteria derived from IBD patient stool that bind to SNK0004 antibody using quantitative data from the IgA Index. Figure 4 shows the results of evaluating the binding characteristics of individual bacterial species for bacteria derived from IBD patient stool that bind to SNK0005 antibody using quantitative data from the IgA Index. FIG. 5 shows the results of testing the ratio of bacteria derived from the stool of IBD patients that bind to the SNK0004 and SNK0005 antibodies, as well as the previously prepared RS_H000_L001, SNK0001, SNK0002, and SNK0003 antibodies ( WO2023 / 277142 ).
[0017] (Definitions) In this specification, when multiple ranges of numerical values are given, the same applies to ranges formed by any combination of the lower and upper limits of those multiple ranges.
[0018] As used herein, the term "antibody" is used in the broadest sense and includes, but is not limited to, monoclonal antibodies, polyclonal antibodies, and antibody fragments that exhibit the intended antigen-binding activity. A full-length antibody comprises a heavy chain and a light chain that are primarily composed of polypeptides. The heavy chain and light chain each contain a region called a variable region that recognizes an antigen, and these regions are generally referred to as the heavy chain variable region and the light chain variable region, respectively. The variable regions each contain CDRs 1 to 3, which are further specified as antigen-recognition sites, in order from the amino terminus. These CDRs 1 to 3 are also more specifically referred to as heavy chain CDR1, heavy chain CDR2, heavy chain CDR3, light chain CDR1, light chain CDR2, light chain CDR3, etc. Furthermore, the regions other than CDRs 1 to 3 of the heavy chain and light chain are referred to as heavy chain FRs 1 to 4 and light chain FRs 1 to 4, in order from the amino terminus.
[0019] The antibody may be in the form of an antibody consisting of two heavy chains and two light chains, or in the form of an antibody consisting of one heavy chain and one light chain (also called a single-chain antibody).Furthermore, the antibody may be in the form of a dimer or multimer having, in addition to two heavy chains and two light chains, a J (joining) chain and, in some cases, an SC (secretary component).
[0020] The antibody may be of any class, such as IgG, IgE, IgM, IgD, IgA, or IgY, or subclass, such as IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2.
[0021] Antibodies may have amino acid sequences derived from the same species or from different species, such as human, mouse, rat, hamster, rabbit, goat, donkey, pig, cow, horse, chicken, monkey, chimpanzee, camel, and llama.
[0022] In the case of antibodies derived from different species, there is no particular limitation, and examples include antibodies derived from two or more of human, mouse, rat, hamster, rabbit, goat, sheep, donkey, pig, cow, horse, chicken, monkey, chimpanzee, camel, llama, etc.
[0023] As used herein, the term "antigen-binding fragment" of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been found that the ability of an antibody to specifically bind to an antigen can also be maintained by fragments consisting of a portion thereof. In one embodiment, the "antigen-binding fragment" of an antibody may be, but is not limited to, a Fab fragment consisting of a light chain variable region (VL), a heavy chain variable region (VH), a light chain constant region (CL), and a CH1 domain that is part of the heavy chain constant region; an F(ab')2 fragment containing two Fab fragments linked by a disulfide bridge at the hinge region; an Fd fragment consisting of the VH and CH1 domains; an Fv fragment consisting of the VL and VH domains of a single antibody arm; a dAb fragment containing a single variable domain; and an isolated complementarity-determining region (CDR).
[0024] The antibody of the present disclosure may be a CDR-grafted antibody. In one example, a CDR-grafted antibody has part or all of the CDR region sequence of an antibody derived from one animal species replaced with the CDR sequence of another animal species. For example, one or more CDRs of a mouse antibody are replaced with the CDR sequence of a human antibody.
[0025] Methods well known to those skilled in the art can be used to identify heavy chain CDR1 to 3 in the heavy chain variable region and light chain CDR1 to 3 in the light chain variable region of an antibody. For example, the "Kabat definition" (Kabat et al., Ann. NY Acad. Sci. 1971, Vol. 190, pp. 382-391 and Kabat, E.A. et al., Sequences of Proteins of Immunological Interest, 5th ed., 1991, U.S. Department of Health and Human Services, NIH Publication, pp. 91-3242), the "Chothia definition" (Chothia et al., Nature, 1989, Vol. 342, pp. 877-883), and the "contact definition" (MacCallum et al., Nature, 1989, Vol. 342, pp. 877-883), all of which are well known to those skilled in the art, may be used. al., J. Mol. Biol., 1996, Vol. 262, pp. 732-745), etc., can be used. To identify CDR sequences within an antibody, CDRs may be identified based on information in public databases (e.g., https: / / www.ncbi.nlm.nih.gov / igblast).
[0026] As used herein, "identity" refers to the degree to which two or more comparable amino acid sequences or nucleotide sequences are identical to each other. Thus, the higher the identity between two amino acid sequences or nucleotide sequences, the higher the identity or similarity between those sequences. The level of identity between amino acid sequences or nucleotide sequences is usually determined using the sequence analysis tool FASTA with default parameters. Alternatively, it can be determined using the BLAST algorithm by Karlin and Altschul (e.g., Karlin S, Altschul S F. Proc. Natl Acad Sci USA. 87:2264-2268 (1990), Karlin S, Altschul S F. Natl Acad Sci USA. 90:5873-7 (1993), etc.). Programs called BLASTN and BLASTX based on such BLAST algorithms have been developed (e.g., Altschul S F, Gish W, Miller W, Myers E W, Lipman D J. J Mol Biol. 215:403-10 (1990)). Specific techniques for these analysis methods are known, and can be found on the NCBI website. For example, when a certain amino acid sequence A is identical to another amino acid sequence B by a certain percentage, this means that amino acid sequence A and amino acid sequence B have the specified percentage of identity.
[0027] As used herein, "monoclonal" is a modifier indicating the character of an antibody or the like obtained from a population of substantially homogeneous antibodies, the individual antibodies within which are identical except for possible naturally occurring mutations that may be present in minor amounts.
[0028] As used herein, the term "conservative substitution techniques" refers to techniques in which an amino acid residue is replaced with an amino acid residue having a similar side chain.
[0029] For example, conservative substitution techniques include substitutions between amino acid residues having basic side chains such as lysine, arginine, and histidine. Other conservative substitution techniques include substitutions between amino acid residues having acidic side chains such as aspartic acid and glutamic acid; amino acid residues having uncharged polar side chains such as glycine, asparagine, glutamine, serine, threonine, tyrosine, and cysteine; amino acid residues having nonpolar side chains such as alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan; amino acid residues having β-branched side chains such as threonine, valine, and isoleucine; and amino acid residues having aromatic side chains such as tyrosine, phenylalanine, tryptophan, and histidine.
[0030] (Antibodies or antigen-binding fragments thereof that bind to C. difficile bacterial bodies) The antibodies that bind to C. difficile bacterial bodies of the present disclosure bind to C. difficile bacteria. Typically, the antibodies of the present disclosure bind to undisrupted C. difficile bacteria present in the culture supernatant.
[0031] The antibodies that bind to C. difficile bacteria of the present disclosure may be produced from antibody-producing cells derived from B cells, such as hybridomas, or may be produced by using genetic recombination technology to introduce nucleic acids encoding the antibodies into cells outside the immune system and used as recombinant antibodies.
[0032] Antibodies that bind to C. difficile bacterial organisms of the present disclosure are preferably IgA antibodies.
[0033] In one embodiment, an antibody that binds to C. difficile bacteria of the present disclosure comprises a heavy chain variable region comprising the amino acid sequence of heavy chain CDR1, the amino acid sequence of heavy chain CDR2, and the amino acid sequence of heavy chain CDR3 of the heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:3, and a light chain variable region comprising the amino acid sequence of light chain CDR1, the amino acid sequence of light chain CDR2, and the amino acid sequence of light chain CDR3 of the light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:4.
[0034] In one embodiment, an antibody that binds to C. difficile bacteria of the present disclosure comprises a heavy chain variable region comprising: a heavy chain CDR1 comprising the amino acid sequence represented by SEQ ID NO:5; a heavy chain CDR2 comprising the amino acid sequence represented by SEQ ID NO:6; and a heavy chain CDR3 comprising the amino acid sequence represented by SEQ ID NO:7; and a light chain variable region comprising: a light chain CDR1 comprising the amino acid sequence represented by SEQ ID NO:8; a light chain CDR2 comprising the amino acid sequence represented by SEQ ID NO:9; and a light chain CDR3 comprising the amino acid sequence represented by SEQ ID NO:10.
[0035] In one embodiment, an antibody that binds to C. difficile bacteria of the present disclosure comprises: a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:1, or a sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto; and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:2, or a sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.
[0036] In one embodiment, an antibody that binds to C. difficile bacteria of the present disclosure comprises: a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:3, or a sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto; and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:4, or a sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto; and a heavy chain variable region comprising: a heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5; a heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6; and a heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7; and a light chain variable region comprising: a light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO:8; a light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO:9; and a light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO:10.
[0037] In one embodiment, the IgA antibody of the present disclosure is SNK0004, which was produced by determining the nucleic acid sequence encoding an IgA antibody produced by a hybridoma obtained from mouse-derived B cells and then applying recombinant technology to produce the IgA antibody. Antibody SNK0004 has the following amino acid sequence:
[0038] In one embodiment, the antibody SNK0004 is encoded by the following nucleic acid sequence:
[0039] In one embodiment, an antibody of the present disclosure that binds to C. difficile bacteria comprises a heavy chain variable region comprising the amino acid sequence of heavy chain CDR1, the amino acid sequence of heavy chain CDR2, and the amino acid sequence of heavy chain CDR3 of the heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13, and a light chain variable region comprising the amino acid sequence of light chain CDR1, the amino acid sequence of light chain CDR2, and the amino acid sequence of light chain CDR3 of the light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 14.
[0040] In one embodiment, an antibody that binds to C. difficile bacteria of the present disclosure comprises a heavy chain variable region comprising: a heavy chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 15; a heavy chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 16; and a heavy chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 17; and a light chain variable region comprising: a light chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 18; a light chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 19; and a light chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 20.
[0041] In one embodiment, an antibody that binds to C. difficile bacteria of the present disclosure comprises: a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13, or a sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto; and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 14, or a sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.
[0042] In one embodiment, an antibody that binds to C. difficile bacteria of the present disclosure comprises: a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13, or a sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto; and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 14, or a sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto; and a heavy chain variable region comprising: a heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15; a heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16; and a heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17; and a light chain variable region comprising: a light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18; a light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 19; and a light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 20.
[0043] In one aspect, the IgA antibody of the present disclosure is SNK0005, which was produced by determining the nucleic acid sequence encoding an IgA antibody produced by a hybridoma obtained from mouse small intestine-derived B cells and then applying recombinant technology to produce the IgA antibody. Antibody SNK0005 has the following amino acid sequence:
[0044] In one embodiment, the antibody SNK0005 is encoded by the following nucleic acid sequence:
[0045] In one embodiment, the antibody according to the present disclosure may be provided in the form of an antibody consisting of one heavy chain and one light chain (also called a single-chain antibody), in addition to a form consisting of two heavy chains and two light chains. Furthermore, the antibody according to the present disclosure may be provided in the form of a dimer or multimer having, in addition to two heavy chains and two light chains, a J (joining) chain and, optionally, an SC (secretary component).
[0046] In one aspect, antibodies of the present disclosure can be provided as any class, such as IgG, IgE, IgM, IgD, IgA, or IgY, or subclass, such as IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2.
[0047] In one aspect, the antibodies of the present disclosure may have amino acid sequences derived from the same species or from different species, such as human, mouse, rat, hamster, rabbit, goat, donkey, pig, cow, horse, chicken, monkey, chimpanzee, camel, or llama.
[0048] In the case of antibodies derived from different species, there is no particular limitation, and examples include antibodies derived from two or more of human, mouse, rat, hamster, rabbit, goat, sheep, donkey, pig, cow, horse, chicken, monkey, chimpanzee, camel, llama, etc.
[0049] (Method for Producing Antibodies that Bind to C. difficile Bacteria) The antibodies that bind to C. difficile bacteria according to the present disclosure can be produced by: (1) preparing immortalized antibody-producing cells from antibody-producing B cells collected from the intestinal lamina propria mucosa; (2) culturing the immortalized antibody-producing cells prepared in step 1 and identifying cells that produce antibodies that bind to C. difficile bacteria; and (3) recovering the antibodies from the cells that produce antibodies that bind to C. difficile bacteria.
[0050] In one embodiment, in order to appropriately combine the heavy chain variable region and / or the light chain variable region as needed, the method may include, for example, a step of treating the heavy chain variable region with a protease or the like, a step of introducing a functional group that enables chemical bonding such as a disulfide bond, and a subsequent step of forming the chemical bond via the functional group.
[0051] When hybridomas are produced by fusing B cells with a type of cell other than B cells, the type of cell other than B cells (sometimes referred to as "other cells" in this specification) is not particularly limited, as long as it fuses with the B cells upon contact to form a hybridoma, and the hybridoma does not lose the antibody-producing function exhibited by the above-mentioned B cells.
[0052] Such other cells are preferably cells that can be fused with the B cells to form hybridomas, and the hybridomas can acquire immortalization functions, and specific examples include cancer cells, particularly cells derived from bone marrow tumors such as myelomas. A preferred other cell is a myeloma, for example, a mouse NS1 cell.
[0053] The origin of the other cells is not particularly limited, but examples include human, mouse, rat, hamster, rabbit, goat, sheep, donkey, pig, cow, horse, chicken, monkey, chimpanzee, camel, and llama.
[0054] Fusion refers to the inseparable union of the B cell with another cell. Here, the term "inseparable union" excludes cell division, which is a phenomenon that occurs when the fused cells grow. Such fused cells are an example of a hybridoma in this specification.
[0055] The conditions for mixing and fusion are not particularly limited, and may be appropriately selected from conditions typically used in cell fusion methods. For example, the conditions used for culturing B cells or other cells may be appropriately modified. Such methods include, for example, a method in which B cells are mixed with a type of cell other than B cells in an appropriate medium and contacted in the presence of polyethylene glycol or the like; a method in which electrical stimulation is applied after the above mixing; or a method in which a virus such as Sendai virus is used, followed by incubation at 37°C in 5% carbon dioxide.
[0056] The time required for fusion is not particularly limited, and may be set as long as the time required for the fusion itself is completed. Completion of fusion can be confirmed by appropriately modifying a known method typically used in cell fusion. Examples of such a method include observing the progress of fusion under a microscope. Cells may be fused using a known kit selected as appropriate under its operating conditions.
[0057] In one embodiment, the specific recovery method in the step of recovering an antibody from cells that produce an antibody that binds to C. difficile bacterial cells is not particularly limited, and examples include a method of recovering the supernatant of a culture medium of antibody-producing cells and a method of recovering a lysate of the cells. The cell lysate can be prepared by lysing the cells using an appropriate combination of known mechanical means such as ultrasonic disruption or French press, and / or known chemical treatments using surfactants, cell wall-digesting enzymes, or cell membrane-digesting enzymes, and then subjecting the cells to a solid-liquid separation step, followed by recovery of the liquid fraction, thereby producing an antibody that binds to C. difficile bacterial cells of the present disclosure.
[0058] (Method for Producing Recombinant Antibody) In one embodiment, an antibody that binds to C. difficile bacteria of the present disclosure is produced by a method in which a nucleic acid encoding the antibody is introduced into cells capable of producing the monoclonal antibody, the cells are cultured, and the monoclonal antibody is recovered from the cell extract or culture supernatant and purified as necessary.
[0059] To confirm that an antibody binds to C. difficile bacteria, means well known to those skilled in the art can be used, for example, by identifying the antibody molecule or the cells that produce the antibody using means such as ELISA, EIA, RIA, FLISA, FIA, or FACS.
[0060] The cells capable of producing the monoclonal antibodies are not particularly limited as long as they are cells capable of producing various proteins derived from mammals or the like that function by forming higher-order structures, and may be appropriately selected from known cells such as mammalian-derived cells such as COS cells, HEK cells (HEK293, HEK293T, etc.), HELA cells, CHO cells, and insect-derived cells such as Sf9. In one embodiment, monoclonal antibodies can also be produced using yeast cells, filamentous fungal cells, or plant cells such as soybean and Arabidopsis thaliana.
[0061] Specific methods for introducing nucleic acids, culture conditions for cells into which the nucleic acids have been introduced, recovery methods, and purification methods vary depending on the type of cells used, and are not particularly limited. By appropriately modifying and combining known methods, it is possible to produce antibodies that bind to the C. difficile bacterial cells according to the present disclosure.
[0062] In one embodiment, monoclonal antibodies can be produced as antibody-containing compositions suitable for enteral intake by producing monoclonal antibodies in these cells, and then drying or lyophilizing the monoclonal antibodies secreted from these cells into the culture medium together with the culture medium, or by crushing, drying, or lyophilizing the monoclonal antibodies accumulated in these cells together with the cells (Virdi et al., Nat. Biotechnol., 2019, Vol. 37, pp. 527-530). In one embodiment, the cells producing the antibody-containing compositions suitable for enteral intake are preferably yeast cells, filamentous fungal cells, or plant cells such as soybean and Arabidopsis thaliana, and the produced monoclonal antibodies are preferably in a form in which a VHH fragment is fused to IgA Fc.
[0063] When the antibody that binds to C. difficile bacteria according to the present disclosure is a chimeric antibody, the above-mentioned nucleic acid can be prepared by preparing nucleic acids having nucleotide sequences encoding heavy and light chain variable regions, as well as nucleotide sequences encoding heterologous heavy and light chain constant regions, binding the prepared nucleotide sequences encoding the heavy chain variable region to a nucleic acid having a nucleotide sequence encoding the heavy chain constant region, and binding the prepared nucleotide sequences encoding the light chain variable region to a nucleic acid having a nucleotide sequence encoding the light chain constant region, and introducing these bound nucleic acids into cells capable of producing antibodies as described above.
[0064] Furthermore, when an antibody that binds to C. difficile bacteria according to the present disclosure is an antibody in which heavy and / or light chain CDR1-3 have amino acid sequences derived from mouse and other regions have amino acid sequences derived from human (these antibodies are sometimes referred to as humanized antibodies), the method of production is similar to that for the chimeric antibody described above: nucleic acids having nucleotide sequences encoding heavy and / or light chain CDR1-3 and nucleotide sequences encoding other regions are prepared, the nucleic acids are recombined to form heavy and light chains, and these are introduced into cells capable of producing monoclonal IgA antibodies as described above. In order to maintain the binding ability of the antibody, it may be necessary to replace some bases with other bases.
[0065] (Nucleic Acid Encoding an Antibody or Antigen-Binding Fragment Thereof That Binds to C. difficile Bacteria) In one aspect, the present disclosure provides a nucleic acid encoding an antibody or antigen-binding fragment thereof that binds to C. difficile bacteria. The nucleic acid encodes the heavy chain and / or light chain of the antibody. The form of the nucleic acid is not particularly limited, and may be ribonucleotides or deoxynucleotides. The form of the nucleic acid is also not particularly limited, and may be single-stranded or double-stranded. The codons used in the nucleic acid sequence are not particularly limited, and various codons can be appropriately selected and used depending on the purpose. For example, codon frequencies can be appropriately selected depending on the type of host cell used during production. In one aspect, a nucleic acid encoding an antibody or antigen-binding fragment thereof of the present disclosure is used to express and produce an antibody or antigen-binding fragment thereof according to the present disclosure.
[0066] When a nucleic acid encoding an antibody or antigen-binding fragment thereof of the present disclosure encodes an antigen-binding fragment, for example, the two domains of the Fv fragment, VL and VH, may be encoded by separate nucleic acid molecules, or, using recombinant techniques, a single protein chain in which the pair of VL and VH domains form a monovalent molecule (single-chain Fv (scFv)) may be encoded by a single nucleic acid.
[0067] In one embodiment, a nucleic acid encoding an antibody or antigen-binding fragment thereof of the present disclosure may be in the form of a vector. For example, the vector may be an expression vector or a vector for use in genetic recombination. The configuration of the vector is not particularly limited and may include various components used in known vectors.
[0068] (Cells Comprising Nucleic Acids Encoding Antibodies or Antigen-Binding Fragments That Bind to C. difficile Bacteria) In one aspect, the present disclosure provides cells comprising nucleic acids encoding antibodies or antigen-binding fragments thereof that bind to C. difficile bacteria. The cells can comprise one or more nucleic acids encoding the heavy chain and / or light chain of the antibodies or antigen-binding fragments thereof of the present disclosure. In one aspect, the cells of the present disclosure produce antibodies or antigen-binding fragments thereof that bind to C. difficile bacteria. In one aspect, the cells of the present disclosure replicate nucleic acids encoding antibodies or antigen-binding fragments thereof that bind to C. difficile bacteria. The type of cells of the present disclosure is not particularly limited, and cells used for protein production, nucleic acid amplification, genetic recombination, etc. can be used. In one aspect, the cells of the present disclosure can be the cells exemplified above (Method for Producing Antibodies That Bind to C. difficile Bacteria) or the cells exemplified below (Antibody-Producing Immortalized Cells).
[0069] (Antibody-Producing Immortalized Cells) In one aspect, the present disclosure provides immortalized cells that produce antibodies that bind to the C. difficile bacterial organisms according to the present disclosure described above.
[0070] Specifically, antibody-producing immortalized cells are cells obtained by fusing antibody-producing B cells with other types of cells, i.e., cells of types other than B cells, or cells that have been made into immortalized B cells by infection with EB virus or the like.
[0071] The hybridomas may be hybridomas derived from the same species or from different species. Hybridomas derived from the same species may be obtained by using the above-mentioned [Method for producing a monoclonal IgA antibody] in which the B cells and the cells other than the B cells are derived from the same species, while hybridomas derived from different species may be obtained by using the B cells and the cells other than the B cells from different species.
[0072] Hybridomas derived from the same species may be appropriately selected from those derived from the same origins of B cells and types of cells other than B cells, among those described in step 1 of the above-mentioned "Method for producing monoclonal IgA antibodies." Examples include hybridomas derived from the same species, such as human, mouse, rat, hamster, rabbit, goat, donkey, pig, cow, horse, chicken, monkey, chimpanzee, camel, and llama.
[0073] The hybridomas of different species may be a combination of cells appropriately selected from the origins of B cells and cells other than B cells described in step 1 of the above-mentioned "Method for producing monoclonal IgA antibodies." Examples of such hybridomas include hybridomas of different species appropriately selected from the origins of human, mouse, rat, hamster, rabbit, goat, sheep, donkey, pig, cow, horse, chicken, monkey, chimpanzee, etc.
[0074] (Composition) In one aspect, the present disclosure provides a composition comprising an antibody or antigen-binding fragment thereof that binds to the C. difficile bacterial organism according to the present disclosure. The composition of the present disclosure is preferably provided as, but is not limited to, a pharmaceutical composition, an oral composition, or an enteral composition.
[0075] (Pharmaceutical Composition) In one aspect, the pharmaceutical composition according to the present disclosure can be suitably used for the treatment of, but is not particularly limited to, diseases associated with, for example, C. difficile bacteria.
[0076] Diseases associated with C. difficile bacteria are not particularly limited, but examples include inflammatory bowel disease, ulcerative colitis, Crohn's disease, allergies, asthma, obesity, autoimmune diseases, and neonatal necrotizing enterocolitis, with inflammatory bowel disease being preferred.
[0077] In one aspect, the pharmaceutical composition according to the present disclosure can be suitably used for improving the intestinal flora.
[0078] Such pharmaceutical compositions according to the present disclosure may contain an effective amount of an antibody or antigen-binding fragment thereof that binds to C. difficile bacteria according to the present disclosure, and can be appropriately determined, for example, so that the content of the antibody according to the present disclosure in 100% by weight of the pharmaceutical composition is in the range of 0.001 to 99.99% by weight, taking into consideration the type of intestinal disease to be treated, the dosage form, the method of administration, the subject, the severity of the subject's symptoms, and the degree of effect exerted by administration.
[0079] As used herein, the term "effective amount" refers to an amount in which an antibody or antigen-binding fragment thereof that binds to C. difficile bacteria according to the present disclosure can exert a therapeutic effect against intestinal diseases and the like.
[0080] Pharmaceutical compositions according to the present disclosure may contain pharmaceutically acceptable carriers or additives in combination with antibodies that bind to C. difficile bacteria according to the present disclosure. The term "pharmaceutically acceptable carriers or additives" refers to any carrier, diluent, excipient, suspending agent, lubricant, adjuvant, vehicle, delivery system, emulsifier, disintegrant, absorbent, preservative, surfactant, colorant, flavoring, or sweetener, and any known pharmaceutically acceptable carrier or additive may be used.
[0081] The pharmaceutical composition according to the present disclosure can be used in a method for treating intestinal diseases, which includes a step of administering the composition to an individual suffering from an intestinal disease associated with the above-mentioned C. difficile bacterium. It can also be used in a method for preventing intestinal diseases, which includes a step of administering the composition to an individual who may be predisposed to an intestinal disease, but who has not yet developed the pathology or symptoms of the intestinal disease. These individuals may be the recipients of the pharmaceutical composition according to the present disclosure.
[0082] Such subjects of administration are not particularly limited, but include mammals such as humans, mice, rats, guinea pigs, rabbits, hamsters, dogs, cats, weasels, cows, and pigs, and birds such as chickens.
[0083] The dosage and administration method of the pharmaceutical composition are appropriately adjusted depending on the type of intestinal disease suffered by the individual to be administered, the sex, species, age, general condition, severity of the disease, the degree of desired effect, etc. The dosage may generally be appropriately set within the range of 0.001 to 100 mg / kg / day.
[0084] The administration method is not particularly limited, but direct administration into the digestive tract is preferred, and examples of such administration methods include oral administration, nasal administration, transmucosal administration, and enteral administration.
[0085] Enteral administration is not limited to administration via the anus, but also includes administration via a tube or the like inserted into the digestive tract from outside the individual, such as a gastrostomy. The location into which the digestive tract is inserted is not limited to the intestine, but may include the esophagus, stomach, small intestine (including the duodenum, jejunum, ileum, etc.), large intestine (including the cecum, colon, rectum, etc.), etc.
[0086] The pharmaceutical composition according to the present disclosure may be administered in the above-mentioned amount once a day or in divided doses. The administration interval may be daily, every other day, weekly, biweekly, every 2-3 weeks, monthly, bimonthly, or every 2-3 months, as long as it has a therapeutic effect against the above-mentioned disease.
[0087] Oral or enteral compositions according to the present disclosure include an antibody or antigen-binding fragment thereof that binds to C. difficile bacteria according to the present disclosure. Use of such oral or enteral compositions can treat and / or prevent diseases associated with C. difficile bacteria and improve the intestinal microflora.
[0088] The proportion of the antibody that binds to C. difficile bacteria in such an oral or enteral composition is not particularly limited and may be adjusted appropriately depending on the form, intended use, etc. of the oral or enteral composition, but is usually about 0.001 to 99% by weight of the total amount of the oral or enteral composition.
[0089] The individual to which the oral or enteral composition according to the present disclosure is to be used is not particularly limited, and examples thereof include mammals such as humans, mice, rats, guinea pigs, rabbits, hamsters, dogs, cats, weasels, cows, and pigs, and birds such as chickens.
[0090] The antibodies that bind to C. difficile bacteria contained in the oral or enteral compositions according to the present disclosure are particularly useful as intestinal regulation compositions, intestinal environment improving compositions, intestinal environment optimizing compositions, or intestinal putrefaction prevention compositions.
[0091] The amount of the oral or enteral composition according to the present disclosure used is not particularly limited as long as it is within a range in which the effects of the oral or enteral composition as described above are exhibited, and may be determined depending on the type of individual ingesting the oral or enteral composition, the desired effect, the desired degree of the effect, and other conditions, etc. Specifically, when converted into the amount of antibodies that bind to C. difficile bacteria according to the present disclosure, the amount is usually about 0.001 to 100 mg / kg / day, which may be taken once or several times a day in divided doses.
[0092] It should be noted that enteral administration is not limited to administration via the anus. For example, the enteral composition of the present disclosure can be formulated with known ingredients and used as an intestinal cleansing liquid.
[0093] The oral or enteral composition according to the present disclosure contains an antibody that binds to the C. difficile bacteria according to the present disclosure, which exhibits the effect of suppressing the abnormal proliferation of intestinal bacteria and / or pathological changes in the intestinal flora, and can be suitably used in the fields of food and feed, expecting to exhibit such effects. Thus, the oral or enteral composition according to the present disclosure can be a food composition or a feed composition.
[0094] The food composition described above is a composition that is suitable for exclusively using the oral or enteral composition of the present disclosure in the field of food, and can be provided as a food composition labeled for intestinal regulation, intestinal environment improvement, intestinal environment optimization, intestinal putrefaction prevention, etc.
[0095] Examples of the food compositions mentioned above include general foods, as well as foods for specified health uses including conditional foods for specified health uses, nutritional supplements, functional foods, and foods for medical patients.
[0096] The specific form of the food composition is not particularly limited, and examples thereof include beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, and dairy drinks; frozen desserts such as ice cream, ice sherbet, and shaved ice; sweets such as candy, candy, gum, chocolate, tablet candy, snacks, biscuits, jelly, jam, cream, and baked goods; noodles such as soba, udon, harusame, Chinese noodles, and instant noodles; processed seafood and livestock foods such as kamaboko, ham, and sausage; dairy products such as processed milk and fermented milk; oils and fats and processed oil foods such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressing; seasonings such as sauces and sauces; soups, stews, salads, side dishes, sprinkles, pickles, bread, and cereals. In the case of foods for specified health uses, nutritional supplements, and functional foods, examples of the food composition include powders, granules, capsules, lozenges, tablets, and syrups.
[0097] The feed composition described above is a composition in which the feed composition of the present disclosure is used exclusively in the field of feed, and such a feed composition can be provided as a food composition labeled for intestinal regulation, intestinal environment improvement, intestinal environment optimization, intestinal putrefaction prevention, etc.
[0098] The specific form of the above-mentioned feed composition is not particularly limited, and for example, as long as the effects exerted by the feed composition according to the present disclosure are not impaired, the feed composition may be prepared by mixing it with ordinary feed or, if necessary, by mixing it with components that can be incorporated into ordinary feed, or the feed composition itself may be used as feed.
[0099] (Method for preventing or treating a disease, or maintaining or improving health) In one aspect, the present disclosure provides a method for preventing or treating an intestinal disease associated with C. difficile bacteria, or a method for maintaining or improving health related to the improvement and maintenance of intestinal microflora, comprising the step of administering to a subject an effective amount of an antibody or antigen-binding fragment thereof that binds to C. difficile bacterial organisms according to the present disclosure, a pharmaceutical composition according to the present disclosure, or an oral composition according to the present disclosure. The subject may be one in need of prevention or treatment of an intestinal disease associated with C. difficile bacteria, or one in need of health maintenance or improvement related to the improvement and maintenance of intestinal microflora.
[0100] Subjects in need of prevention or treatment of the intestinal disease associated with the above-mentioned C. difficile bacteria can be selected from those described in the "pharmaceutical composition" of the present disclosure. Furthermore, subjects in need of health maintenance or improvement related to the improvement and maintenance of the intestinal flora are not particularly limited, and include subjects in whom the maintenance or improvement of the intestinal flora is desirable.
[0101] Such subjects of administration are not particularly limited, but include mammals such as humans, mice, rats, guinea pigs, rabbits, hamsters, dogs, cats, weasels, cows, and pigs, and birds such as chickens.
[0102] Specific administration methods and dosages can be those explained in the [pharmaceutical composition] or [oral or enteral composition] according to the present disclosure above.
[0103] For example, when administered as a pharmaceutical composition, the dosage and administration method of the composition are appropriately adjusted depending on the type of intestinal disease suffered by the individual to be administered, the sex, species, age, general condition, severity of the disease, the degree of the desired effect, etc. The dosage may generally be appropriately set within the range of 0.001 to 100 mg / kg / day.
[0104] The administration method is not particularly limited, but direct administration into the digestive tract is preferred, and examples of such administration methods include oral administration, nasal administration, transmucosal administration, and enteral administration.
[0105] Enteral administration is not limited to administration via the anus, but also includes administration via a tube or the like inserted into the digestive tract from outside the individual, such as a gastrostomy. The location into which the digestive tract is inserted is not limited to the intestine, but includes the esophagus, stomach, small intestine (including the duodenum, jejunum, ileum, etc.), large intestine (including the cecum, colon, rectum, etc.), etc.
[0106] The pharmaceutical composition may be administered in the above-mentioned amount once a day or in divided doses several times a day. Furthermore, the administration interval may be daily, every other day, weekly, biweekly, every 2-3 weeks, monthly, bimonthly, or every 2-3 months, as long as it has a therapeutic effect against the above-mentioned diseases.
[0107] The pharmaceutical composition may contain an effective amount of an antibody or antigen-binding fragment thereof that binds to C. difficile bacteria according to the present disclosure, and can be appropriately determined, for example, so that the content of the antibody according to the present disclosure in 100% by weight of the composition is in the range of 0.001 to 99.99% by weight, taking into consideration the type of intestinal disease to be treated, the dosage form, the method of administration, the subject, the severity of the subject's symptoms, and the degree of effect exerted by administration.
[0108] Pharmaceutical compositions may contain a pharmaceutically acceptable carrier or additive together with an antibody or antigen-binding fragment thereof that binds to C. difficile bacteria according to the present disclosure. The term "pharmaceutically acceptable carrier or additive" refers to any known carrier, diluent, excipient, suspending agent, lubricant, adjuvant, vehicle, delivery system, emulsifier, disintegrant, absorbent, preservative, surfactant, colorant, flavoring, or sweetener.
[0109] Pharmaceutical compositions may contain a pharmaceutically acceptable carrier or additive together with an antibody or antigen-binding fragment thereof that binds to C. difficile bacteria according to the present disclosure. The term "pharmaceutically acceptable carrier or additive" refers to any known carrier, diluent, excipient, suspending agent, lubricant, adjuvant, vehicle, delivery system, emulsifier, disintegrant, absorbent, preservative, surfactant, colorant, flavoring, or sweetener.
[0110] When the composition is administered orally or enterally, the dosage is not particularly limited as long as it is within a range in which the effect of the composition is exerted, and may be determined depending on the type of individual ingesting the oral or enteral composition, the desired effect, the desired degree of the effect, and other conditions. Specifically, the dosage, converted into the amount of antibodies that bind to C. difficile bacteria according to the present disclosure, is usually about 0.001 to 100 mg / kg / day, which may be taken once or several times a day in divided doses.
[0111] It should be noted that enteral administration is not limited to administration via the anus. For example, the enteral composition of the present disclosure can be formulated with known ingredients and used as an intestinal cleansing liquid.
[0112] Oral or enteral compositions may be administered as food or feed compositions.
[0113] The food composition can be administered as a food composition labeled for intestinal regulation, improvement of intestinal environment, optimization of intestinal environment, prevention of intestinal putrefaction, etc.
[0114] The food composition can be administered as a general food, a food for specified health uses including conditional foods for specified health uses, a nutritional supplement, a functional food, a food for the sick, or the like.
[0115] The specific form of the food composition is not particularly limited, and examples thereof include beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, and dairy drinks; frozen desserts such as ice cream, ice sherbet, and shaved ice; sweets such as candy, candy, gum, chocolate, tablet candy, snacks, biscuits, jelly, jam, cream, and baked goods; noodles such as soba, udon, harusame, Chinese noodles, and instant noodles; processed seafood and livestock foods such as kamaboko, ham, and sausage; dairy products such as processed milk and fermented milk; oils and fats and oil-based foods such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressing; seasonings such as sauces and sauces; soups, stews, salads, side dishes, sprinkles, pickles, bread, and cereals. In addition, in the case of foods for specified health uses, dietary supplements, and functional foods, they can be administered in the form of powders, granules, capsules, lozenges, tablets, syrups, and the like.
[0116] The feed composition can be administered as a food composition labeled for intestinal regulation, intestinal environment improvement, intestinal environment optimization, intestinal putrefaction prevention, etc.
[0117] The specific form of the feed composition is not particularly limited, and for example, as long as the effects of the feed composition according to the present disclosure described above are not impaired, the feed composition may be prepared by mixing it with ordinary feed or, if necessary, by mixing it with components that can be incorporated into ordinary feed, or the feed composition itself may be administered as feed.
[0118] Hereinafter, the present disclosure will be described in more detail with reference to examples, but these are merely illustrative and do not limit the present disclosure.
[0119] Example 1: Obtaining Antibodies That Bind to C. difficile Antibodies that bind to C. difficile were obtained using the following method. (Materials and Methods) (1-1) Isolation of Small Intestinal and Large Intestinal Lamina Propria Cells Mice were euthanized, and the entire length of the small intestine was excised through abdominal surgery. After removing connective tissue and Peyer's patches from the excised small intestine, the small intestine was incised longitudinally and the contents were washed with PBS. Next, the washed small intestine was cut into approximately 1 cm lengths and added to a 100 ml beaker filled with 50 ml of PBS containing 1 mM EDTA. After shaking at 37°C for 20 minutes, the small intestinal fragments were collected in a strainer, and the PBS containing EDTA was discarded. The small intestinal fragments were added to a 50 ml tube, 20 ml of PBS was added, and the tube was shaken vigorously for 10 seconds. The small intestinal fragments were then collected again in a strainer, and the PBS was discarded. This process was repeated twice to remove only small intestinal epithelial cells from the small intestinal tissue. Next, 50 ml of digestive enzyme solution (adjusted to 100 ml RPMI 1640, 5 ml FCS (final concentration 5%), 50 μl 2-mercaptoethanol (final concentration 55 μM), 0.15 g collagenase, and 1 ml dispase (50 U / ml) (final concentration 0.5 U / ml)) preheated to 37°C was added to a 100 ml beaker, and the small intestinal tissue was further finely chopped and added. The mixture was then shaken at 37°C for 30 minutes. The 100 ml beaker was then left to settle the small intestinal tissue, and the supernatant was transferred to a new 50 ml tube. This digestion process using the digestive enzyme solution was repeated once for 20 minutes. The digestive solution was centrifuged at 1,500 rpm at room temperature for 5 minutes, and the supernatant was discarded. The lamina propria cells obtained as a precipitate were washed once with RPMI 1640 containing 2% FCS, then suspended in 2 ml of RPMI 1640 containing 2% FCS and stored on ice. The same procedure was performed on the supernatant from the second digestion step, and the first and second cell suspensions were combined and passed through a filter to remove tissue debris, yielding small intestinal (large intestinal) lamina propria cells.
[0120] (1-2) Preparation and Cloning of Antibody-Producing Hybridomas Hybridomas were prepared by fusing small intestinal (colon) mucosal cells or spleen cells with mouse myeloma cells, NS1 cells. Cell fusion was performed according to the ClonaCell-HY Hybridoma Cloning Kit (STEMCELL Technologies) using the kit's reagents and procedures. The obtained hybridomas were grown in methylcellulose-containing medium according to the ClonaCell-HY Hybridoma Cloning Kit (STEMCELL Technologies), clones were picked visually, and each clone was further grown in a 96-well plate. Frozen cell stocks were then prepared from the cloned hybridomas, and the culture supernatant was simultaneously obtained. The isotype of the antibodies contained in the supernatant was confirmed by a conventional sandwich ELISA method, and then the antibody titer of the antibodies contained in the supernatant was measured, and hybridomas producing antibodies of each isotype were isolated. The antibodies used in ELISA were anti-goat-mouse IgA (Southern Biotech), anti-goat-mouse IgG (Southern Biotech), or anti-goat-mouse IgM (Southern Biotech) at 2 μg / ml for coating the plate, and alkaline phosphatase (ALP)-conjugated anti-goat-mouse IgA (Southern Biotech) or alkaline phosphatase (ALP)-conjugated anti-goat-mouse IgG (Southern Biotech) for detection. Anti-goat mouse IgM (Southern Biotech) or alkaline phosphatase (ALP)-conjugated anti-goat mouse IgM (Southern Biotech) was used at 0.5 μg / ml.Control antibodies used were mouse IgAκ (Immunology Consultants Laboratory), purified mouse IgG1κ isotype control (BD Pharmingen), and PE-CF594 mouse IgMκ isotype control (BD Horizon). Measurements were performed using TriStar. 2 LB942 (BERTHOLD TECHNOLOGIES) is used, and 405 By the above procedures, a total of 500 or more hybridoma clones were obtained.
[0121] (1-3) Analysis of the binding strength of hybridoma IgA antibodies to C. difficile C. difficile was cultured anaerobically at 37°C (Brain Heart Infusion media, 80% N 2 , 10% H 2 , 10% CO 2 ) and collected by centrifugation. 2 CO 3 Bacteria were suspended in buffer and coated onto an ELISA plate. After blocking with 1% BSA-supplemented PBS, the culture supernatants of each antibody in a 96-well plate were added and allowed to react at room temperature for approximately 1 hour. The plate was then washed with 0.05% Tween 20-supplemented PBS, and a secondary detection antibody (described above) corresponding to each antibody isotype was added and reacted. After the reaction, a color reaction was carried out using an Alkali Phosphatase tablet (Sigma). To ensure sufficient reaction, the ELISA plate after color development was incubated overnight at 4°C and then incubated with TriStar. 2 LB942 (BERTHOLD TECHNOLOGIES) is used, and 405 nm was measured. 405 Clones that showed an nm of 2.0 or more were determined to be antibodies that bind to C. difficile bacteria.
[0122] The selected clones were cultured and expanded (approximately 100 mL), and antibodies were purified from the culture medium using a Protein L column (Cytiva) for IgM and IgA antibodies, and a Protein A column (Cytiva) for IgG antibodies. The antibodies were eluted using 10 mM citrate buffer (pH 2.5). The eluate was immediately neutralized with 1 M citrate buffer (pH 9.0), concentrated using an Amicon (100 kDa), dialyzed against a dialysis membrane (100 kDa pore size), and replaced with PBS. After dialysis, the antibody solution was collected in a clean bench and sterilized using a syringe filter (0.22 μm) and stored at 4°C. The antibody concentration was measured by sandwich ELISA as described above. RNA from clones selected by ELISA was extracted, and the full-length antibody gene was cloned and used to produce recombinant antibodies.
[0123] (1-4) Cloning of full-length antibody genes of hybridoma-derived antibodies RNA was extracted from the cells of each clone using Isogen II (Nippon Gene Co., Ltd.). cDNA was synthesized using the extracted RNA as a template, and the V H RT-PCR was performed using seven primers (MH1-7) specific to the Cα region, Cμ region, or Cγ region. For the light chain, PCR was performed using Vκ primers and Cκ primers. The base sequences of the primers are shown in Table 1. The amplified V H The Vκ region PCR products or Vκ region PCR products were directly sequenced to obtain the variable region gene sequences of each clone. H Alternatively, a sequence further upstream of the Vκ gene (including the signal sequence) was obtained, and PCR primers were prepared based on the upstream sequence. PCR was performed with a reverse primer at the 3' end of each C region secretory sequence to obtain the full-length gene sequences of the H and L chains. Based on this, the H, L, and J chains were cloned into the pcDNA 3.1(+) vector (Invitrogen) (the full-length gene sequences were obtained by PCR using hybridoma cDNA after searching for the base sequence in a database). Table 1. Nucleotide sequences of primers for amplifying the variable regions of hybridoma-derived antibodies. In the nucleotide sequences in the table, S represents G or C, R represents A or G, N represents A, C, G, or T, W represents A or T, V represents G, C, or A, and M represents A or C. The above expression vectors were transfected into Expi CHOS cells (Thermo Fischer Scientific) at a quantitative ratio of H:L:J = 2:1:1 according to the kit protocol (Thermo Fischer Scientific, ExpiCHO Expression System). The culture supernatant was collected 10-12 days after transfection, and the antibody was purified and concentrated using a Protein L column as described above. After dialysis against PBS, the antibody was filter-sterilized and used for antibody titer measurement and activity testing.
[0124] Example 2: Bacterial binding test Of the antibodies obtained in Example 1, two, SNK0004 antibody and SNK0005 antibody, were tested for their binding ability to C. difficile bacteria. The test method used was the same as that in (1-3) "Analysis of binding ability of hybridoma IgA antibodies to C. difficile bacteria" in Example 1. As can be seen from the results shown in Figure 1, both antibodies demonstrated binding to C. difficile bacteria.
[0125] Example 3: Bacterial growth inhibition test The bacterial growth inhibitory effects of SNK0004 antibody, SNK0005 antibody, IgG1 type antibody of W27 antibody (rW27IgG), and negative control IgA (Control rIgA) were tested.
[0126] (Materials and Methods) C. difficile bacteria were cultured anaerobically overnight at 37°C under the same conditions as in Example 1. The culture medium was centrifuged, the bacteria were collected, and then washed twice with culture medium. The bacterial solution was diluted 10-fold with culture medium, and counting beads and thiazol orange included in the Cell Viability Kit (Becton Dickinson) were added. The number of SYTO24-positive live bacteria was calculated by comparison with the counting beads using flow cytometry. The bacteria were diluted with culture medium to 10,000 cells / 5 μl. 5 μl of the bacterial dilution was added to an Eppendorf tube, followed by 25 μl of PBS (anaerobic) or 25 μl of purified test antibody (anaerobic) (antibody concentration 1 mg / ml), and the mixture was incubated at 37°C for 1 hour. Thereafter, 30 μl of the culture medium was added, and static anaerobic culture was carried out at 37° C. for 6 hours (final antibody concentration: 0.42 mg / ml). After 6 hours, the reaction mixture was serially diluted and inoculated onto BHI agar plates, followed by anaerobically culturing at 37° C., and the viable bacterial count was counted.
[0127] (Results) The results are shown in Figure 2. Both the tested SNK0004 and SNK0005 antibodies exhibited a significant ability to inhibit the proliferation of C. difficile compared to the IgG1 type antibody of the W27 antibody (rW27IgG) and the negative control IgA antibody (Control rIgA).
[0128] Example 4: Binding properties to human intestinal bacteria Dysbiosis of the intestinal microbiota has been reported to be associated with the onset of many diseases, including inflammatory bowel disease (IBD), and improving the intestinal microbiota is considered important for maintaining health. It has been found that the state of the intestinal microbiota of patients with inflammatory bowel disease (IBD) differs from that of healthy individuals, and that bacteria associated with the exacerbation of IBD (IBD-associated bacteria) are increased (PCT / JP2023 / 018019).
[0129] The binding characteristics of individual bacterial species derived from feces of IBD patients that bind to the SNK0004 and SNK0005 antibodies were evaluated using quantitative data obtained by IgA Index (Andrew L. Kau, et al., Sci Transl Med 7, 2015; Hirosuke Sugahara, et al., Frontiers in Microbiology 8, 1757, 2017).
[0130] (Materials and Methods) Analysis of the ratio of IgA antibody-binding bacteria to bacteria in human stool samples. The stool of one patient (P1) was used as the human stool sample. The procedure was carried out in an anaerobic chamber. After measuring the number of bacteria, the bacteria in the human stool sample were diluted to 6 x 10 by adding PBS. 7 The culture was adjusted to a concentration of 6 × 10 cells / ml. The culture was then centrifuged at 8,000 g for 5 minutes at 4°C, and the supernatant was removed. 100 μl of PBS containing 20% normal rat serum (Wako) was added to the supernatant-removed cells, and the cells were incubated on ice for 30 minutes. This inhibited nonspecific binding of the antibody. Fluorescence-activated cell sorter (FACS) buffer for antibody staining was prepared by adding 10% fetal bovine serum (FBS, Nichirei) and EDTA (final concentration 5 μM, Nacalai Tesque) to PBS, and sterilizing the mixture through a 0.22 μm filter. The FACS buffer was added to the culture, and the mixture was centrifuged at 8,000 g for 5 minutes at 4°C, and the supernatant was removed. The bacterial count was 6 × 10 6 15 μg of each biotinylated antibody was added to each cell, and the mixture was incubated on ice for 20 minutes. FACS buffer was added to the antibody reaction mixture, and the mixture was centrifuged at 8,000 g for 5 minutes at 4°C, and the supernatant was removed. 20 μl of PE / Cyanine 7-Streptavidin (final concentration 10 μg / ml, BioLegend) was added to the bacterial cells, and the mixture was incubated on ice for 20 minutes in the dark. FACS buffer was added to the reaction mixture, and the mixture was centrifuged at 8,000 g for 5 minutes at 4°C, and the supernatant was removed. FACS buffer and thiazole orange (final concentration 42 nM, BD) were added to the bacteria, and the mixture was incubated on ice for 10 minutes. The percentage of bacteria bound to each antibody was then analyzed using a Sony Cell Sorter SH800 (Sony).
[0131] Results: Enterobacteriaceae showed specific binding to both SNK0004 and SNK0005, and it was revealed that other bacteria also bound to these antibodies with different binding properties (Figs. 3 and 4).
[0132] The proportions of bacteria derived from IBD patient stool samples (from one patient (P1)) that bind to the SNK0004 and SNK0005 antibodies and the previously prepared RS_H000_L001, SNK0001, SNK0002, and SNK0003 antibodies (WO 2023 / 277142) were compared. As shown in Figure 5, all of these antibodies bind to Enterobacteriaceae, suggesting that they have the effect of improving the intestinal flora.
[0133] From the above results, it is understood that the SNK0004 and SNK0005 antibodies bind to bacteria present in dysbiotic intestinal flora and have the effect of improving the intestinal flora.
[0134] INDUSTRIAL APPLICABILITY The present disclosure has extremely high industrial value by providing antibodies and antigen-binding fragments thereof that specifically bind to Clostridioides difficile (C. difficile), as well as uses thereof.
[0135] Sequence information
Claims
1. An antibody or antigen-binding fragment thereof, which binds to Clostridioides difficile bacteria and inhibits the growth of Clostridioides difficile, and comprises: heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 of a heavy chain variable region represented by SEQ ID NO: 3; and light chain CDR1, light chain CDR2, and light chain CDR3 of a light chain variable region represented by SEQ ID NO: 4; or heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 of a heavy chain variable region represented by SEQ ID NO: 13; and light chain CDR1, light chain CDR2, and light chain CDR3 of a light chain variable region represented by SEQ ID NO:
14.
2. The antibody or antigen-binding fragment thereof according to claim 1, comprising a heavy chain CDR1 represented by sequence number 5, a heavy chain CDR2 represented by sequence number 6, a heavy chain CDR3 represented by sequence number 7; and a light chain CDR1 represented by sequence number 8, a light chain CDR2 represented by sequence number 9, and a light chain CDR3 represented by sequence number 10.
3. The antibody or antigen-binding fragment thereof according to claim 1, comprising a heavy chain CDR1 represented by SEQ ID NO: 15, a heavy chain CDR2 represented by SEQ ID NO: 16, a heavy chain CDR3 represented by SEQ ID NO: 17; and a light chain CDR1 represented by SEQ ID NO: 18, a light chain CDR2 represented by SEQ ID NO: 19, and a light chain CDR3 represented by SEQ ID NO:
20.
4. A nucleic acid encoding the antibody or antigen-binding fragment thereof of claim 1.
5. An expression vector comprising the nucleic acid according to claim 4.
6. A cell comprising the nucleic acid according to claim 4.
7. A composition comprising the antibody or antigen-binding fragment thereof described in claim 1.
8. The composition according to claim 7, which is in a freeze-dried state.
Citation Information
Patent Citations
Method and composition both for treating or diagnosing inflammatory bowel disease (IBD)
WO2023219175A1
METHOD FOR PRODUCING MONOCLONAL IgA ANTIBODY
WO2014142084A1
Antibody binding to clostridium difficile
WO2023277142A1
Monoclonal antibody-containing composition for suppressing clostridium difficile bacteria
WO2023277166A1
